Sunshine Biopharma (SBFM) Interest Expenses (2012 - 2026)
Sunshine Biopharma (SBFM) posted Interest Expenses of $180634.0 for Q1 2026, down 5.33% on a QoQ basis from $190801.0 in Q3 2025, and down 2.23% year-over-year from $184762.0 in Q1 2025.
Sunshine Biopharma (SBFM) Interest Expenses (2012 - 2026) Analysis & Trends
Sunshine Biopharma's Interest Expenses history runs 14 years deep, the most recent figure standing at $180634.0 for Q1 2026.
- Quarterly Interest Expenses fell 2.23% year-over-year to $180634.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180634.0 (down 2.23% YoY) and the FY2025 annual result came in at $8.4 million, up 21.22% from the prior year.
- Interest Expenses was $180634.0 for Q1 2026 at Sunshine Biopharma, down from $190801.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $194689.0 in Q2 2025 and bottomed at $2.0 in Q3 2022.
- A 5-year average of $97830.0 and a median of $103636.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 100.0% — and 2023, when it surged 5506600.0%.
- Sunshine Biopharma's Interest Expenses stood at $26546.0 in 2022, then rose by 13.43% to $30110.0 in 2023, then slumped by 71.67% to $8529.0 in 2024, then surged by 2137.09% to $190801.0 in 2025, then fell by 5.33% to $180634.0 in 2026.
- Business Quant data shows SBFM's Interest Expenses at $180634.0 in Q1 2026, $190801.0 in Q3 2025, and $194689.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 1.77 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 180,634.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180,634.00 |
| Mar 31, 2026 | 180,634.00 |
| Sep 30, 2025 | 190,801.00 |
| Sep 30, 2025 | 190,801.00 |
| Jun 30, 2025 | 194,689.00 |
| Jun 30, 2025 | 194,689.00 |
| Mar 31, 2025 | 184,762.00 |
| Mar 31, 2025 | 184,762.00 |
| Dec 31, 2024 | 8,529.00 |
| Dec 31, 2024 | 8,529.00 |
| Sep 30, 2024 | 103,897.00 |
| Sep 30, 2024 | 103,897.00 |
| Jun 30, 2024 | 102,470.00 |
| Jun 30, 2024 | 102,470.00 |
| Mar 31, 2024 | 103,506.00 |
| Mar 31, 2024 | 103,506.00 |
| Dec 31, 2023 | 30,110.00 |
| Dec 31, 2023 | 30,110.00 |
| Sep 30, 2023 | 110,134.00 |
| Sep 30, 2023 | 110,134.00 |